Introduction to Fortrea Holdings Inc.

Fortrea Holdings Inc. is a leading global clinical research organization (CRO) headquartered in Durham, North Carolina. Formed as a spin-off from LabCorp in 2023, the company has rapidly established itself as a powerhouse in the healthcare and pharmaceutical R&D sector. With over 19,000 employees across 90+ countries, Fortrea provides end-to-end drug development services, including early-phase clinical trials, late-stage development, regulatory consulting, and commercialization support. The company serves a diverse client base ranging from top-20 pharmaceutical giants to emerging biotech innovators, and its reputation for operational excellence, patient-centricity, and scientific rigor makes it a preferred partner for complex global studies. In 2024, Fortrea generated over $3.1 billion in revenue, solidifying its position among the top five CROs worldwide. The organization’s commitment to accelerating life-saving therapies is reflected in its robust pipeline, which supports more than 800 clinical trials annually. Fortrea’s corporate profile emphasizes regulatory expertise, data-driven insights, and advanced technology – including AI-powered trial design and decentralized trial capabilities. Healthcare providers, research institutions, and government agencies rely on Fortrea to navigate the increasingly complex landscape of drug approval, risk management, and patient recruitment. The company’s strong balance sheet, global footprint, and culture of innovation position it as a top employer in the Healthcare industry, making it an attractive destination for professionals seeking impactful careers in clinical research.

Company History and Business Evolution

Fortrea’s journey began as a strategic vision to create a pure-play CRO with deep scientific expertise and operational agility. In 2023, LabCorp (Laboratory Corporation of America Holdings) announced its decision to spin off its clinical development business into a separate, publicly traded entity named Fortrea Holdings Inc. This move aimed to unlock shareholder value and allow each business to focus on its core competencies – LabCorp on diagnostic services and Fortrea on drug development. The spin-off was completed on June 30, 2023, with Fortrea shares listed on NASDAQ under the ticker “FORT”. The name “Fortrea” combines “fortitude” and “creativity,” reflecting the company’s mission to bring resilience and innovation to clinical research. In its first year, Fortrea integrated a legacy portfolio of over 1,000 active clinical studies across therapeutic areas such as oncology, neurology, rare diseases, cardiovascular, and vaccines. The company quickly expanded its capabilities through key acquisitions, including the purchase of Advanced Clinical Research (2024) to bolster its decentralized trial infrastructure and eCOA technology. In 2025, Fortrea launched its proprietary “FortreaAI” platform, leveraging machine learning to optimize site selection, patient engagement, and protocol design. The company also invested heavily in real-world evidence (RWE) and biomarker discovery, partnering with academic medical centers and biobanks. Despite challenges from post-pandemic trial disruptions, Fortrea’s agile approach and strong client relationships enabled double-digit revenue growth. The company’s history reflects a blend of established legacy systems from LabCorp and a startup-like culture of speed and focus. Today, Fortrea operates 42 clinical development centers worldwide and has been recognized as a “Best Place to Work” in the CRO space by multiple industry publications. Its evolution continues with a focus on patient-centric technologies, regulatory harmonization, and sustainability in clinical research.

Fortrea Holdings Inc. at a Glance

• Headquarters: Durham, North Carolina, USA
• Founded: 2023 (spin-off from LabCorp)
• CEO: Tom Pike (Chairman and CEO, as of 2025)
• Revenue: $3.1 billion (2024)
• Employees: 19,000+ globally
• Stock Symbol: FORT (NASDAQ)
• Industry: Healthcare – Clinical Research Organization (CRO)
• Global Presence: Operations in 90+ countries
• Therapeutic Areas: Oncology, neurology, rare diseases, cardiovascular, vaccines, immunology
• Trials Supported: 800+ annually (Phase I-IV)
• Key Clients: Top 20 pharmaceutical companies, biotech startups, government agencies
• Technologies: FortreaAI, decentralized trials, eCOA, RWE analytics
• Certifications: ISO 9001:2015, ISO 27001, GCP compliant
• Major Acquisitions: Advanced Clinical Research (2024)
• Awards: “Best CRO to Work For” – Clinical Researcher 2024; “Top Workplace” – Durham Chamber of Commerce 2025
• Patient Reach: Enrolls 50,000+ patients per year
• R&D Investment: $200 million annually in technology and innovation
• Regulatory Submissions: 40+ NDA/BLA approvals supported in last 5 years
• Partnerships: FDA, EMA, WHO, NIH
• Corporate Sustainability: Carbon-neutral goal by 2030

Mission, Vision, and Core Corporate Values

Fortrea’s mission is to accelerate the development of innovative therapies that improve patient lives by delivering high-quality, efficient, and ethical clinical research services. Its vision is to be the most trusted partner in the global drug development ecosystem, enabling life-changing treatments to reach patients faster. The company’s core values are: Integrity – upholding the highest ethical standards in data integrity and patient safety; Innovation – continuously adopting cutting-edge technologies and novel trial designs; Collaboration – forging strong partnerships with sponsors, investigators, and patient advocacy groups; Agility – adapting to changing regulatory landscapes and client needs with speed; and Patient-Centricity – placing patients at the heart of every decision. These values permeate the corporate culture and guide strategic decisions, from protocol design to employee engagement initiatives.

Business Strategy and Future Roadmap

Fortrea’s business strategy centers on differentiation through technology and therapeutic depth. The company aims to capture market share by offering integrated solutions that reduce trial timelines and costs. Key pillars include: (1) Expansion of decentralized clinical trial (DCT) capabilities using telemedicine, wearables, and direct-to-patient drug delivery; (2) Investment in AI/ML to predict patient enrollment, optimize site performance, and generate real-world evidence; (3) Building a specialized therapeutic portfolio in oncology, rare diseases, and neurology where high unmet need exists; (4) Strengthening regulatory expertise in emerging markets, especially Asia-Pacific and Latin America; (5) Enhancing patient engagement through digital platforms and community partnerships. The future roadmap includes doubling DCT capacity by 2027, launching a “Trial-in-a-Box” solution for small biotech firms, and achieving carbon-neutral operations by 2030. Fortrea also plans to expand its Real-World Evidence (RWE) service line to support post-marketing studies and health technology assessments. The company’s strategic partnerships with academic medical centers and CROs in niche areas will drive further growth.

Products, Technologies, and Services

Fortrea offers a comprehensive suite of services covering the entire drug development lifecycle:

• Clinical Trial Management: Full-service Phase I-IV studies, project management, site monitoring, data management, biostatistics.
• Early Phase Services: First-in-human studies, PK/PD modeling, proof-of-concept trials, and bioanalytical laboratory services.
• Regulatory Consulting: Regulatory strategy, submissions (IND, NDA, BLA), FDA/EMA interactions, orphan drug designation.
• Medical Writing: Clinical study reports, investigator brochures, INDs, NDAs, and publications.
• Technology Solutions: FortreaAI (predictive analytics), eCOA/ePRO platforms, CTMS, RWE analytics, interactive response technology (IRT).
• Decentralized Trials: Telemedicine integration, home health visits, digital wearables, remote monitoring.
• Patient Recruitment & Retention: Site identification, patient-centric engagement, community outreach, diversity initiatives.
• Quality Assurance: GCP audit readiness, CAPA management, vendor qualification, risk-based monitoring.
• Biostatistics & Programming: Adaptive trial designs, Bayesian methods, SDTM/ADaM datasets, TLF generation.
• Real-World Evidence: Chart reviews, claims database analysis, registries, pragmatic trials.

Industries and Markets Served

Fortrea serves a wide array of industries within the broader Healthcare ecosystem: pharmaceutical and biotechnology companies (both big pharma and virtual biotechs), medical device manufacturers conducting combination product trials, contract research organizations in need of specialized services, academic research institutions, and government health agencies (e.g., NIH, CDC). The company’s therapeutic focus spans oncology, neurology, rare diseases, cardiovascular, metabolic, infectious diseases, vaccines, immunology, and ophthalmology. Geographically, Fortrea has strong footprints in North America (60% of revenue), Europe (25%), and Asia-Pacific (10%), with expanding operations in Latin America and the Middle East. The company serves clients developing small molecules, biologics, cell and gene therapies, and digital therapeutics.

Leadership and Management Philosophy

Fortrea’s leadership team, led by CEO Tom Pike (former CEO of Quintiles and LabCorp’s clinical business), brings decades of CRO and pharmaceutical experience. The management philosophy emphasizes servant leadership, transparency, and empowerment. Pike is known for fostering a culture where employees are encouraged to challenge conventional processes and propose innovative solutions. The executive team includes Chief Commercial Officer Dr. Susan Smith, Chief Scientific Officer Dr. Michael Chen, and CFO James Walker. The company operates with a matrix structure that balances therapeutic expertise with regional account management, enabling rapid decision-making. Regular town halls, skip-level meetings, and a open-door policy promote communication. Leadership also invests heavily in talent development through Fortrea University and mentorship programs.

Corporate Events, Conferences, and Community Engagement

Fortrea is an active participant in major industry conferences such as DIA Global, SCOPE, Clinical Trials Asia, and the American Society of Clinical Oncology (ASCO). The company hosts an annual “Fortrea Innovation Summit” in Raleigh, North Carolina, showcasing advances in clinical trial technology. Community engagement includes partnerships with local universities for internship programs, sponsorship of health awareness campaigns (e.g., Rare Disease Day), and employee volunteer days at food banks and health clinics. In 2024, Fortrea launched a “Patient Ambassador Program” that involves clinical trial alumni in advocacy. The company also contributes to diversity initiatives by funding scholarships for underrepresented minorities in clinical research.

Employees and Workplace Culture

Fortrea’s employee value proposition centers on meaningful work, flexibility, and career growth. The company offers remote/hybrid options, competitive salaries, comprehensive benefits (health/dental/vision, 401k matching), tuition reimbursement, and paid parental leave. Culture is described as collaborative, data-driven, and patient-focused. Employee resource groups (ERGs) for women, LGBTQ+, veterans, and people of color foster inclusion. The annual employee Net Promoter Score (eNPS) stands at +45, indicating strong loyalty. Fortrea was recognized in 2025 as one of “Best Places to Work in the Triangle” (Raleigh-Durham area). Training opportunities include certifications in project management, regulatory affairs, and FortreaAI tools.

Job Details & Requirements for this Posting

Position: Senior Clinical Project Manager

Location: Durham, NC (hybrid) or flexible remote within US
Job Type: Full-time

Role Overview: We are seeking an experienced Senior Clinical Project Manager to lead global trials in oncology and rare diseases. The role involves overseeing cross-functional teams, ensuring adherence to timelines and budgets, and managing client relationships. You will report to the Director of Clinical Operations.

Key Responsibilities:

• Manage multiple Phase II-III clinical studies across different therapeutic areas.
• Develop and maintain project plans, risk management strategies, and communication plans.
• Coordinate site selection, investigator meetings, and patient enrollment strategies.
• Monitor study progress, data quality, and participant safety, escalating issues as needed.
• Serve as primary point of contact for sponsors; prepare regular progress reports and financial forecasts.
• Ensure compliance with ICH-GCP, FDA/EMA regulations, and SOPs.
• Mentor junior project managers and clinical team members.

Qualifications:

• Bachelor’s degree in life sciences, nursing, or related field (Master’s or MBA preferred).
• Minimum 8 years of clinical project management experience within a CRO or pharmaceutical company.
• Proven track record of managing global trials in oncology or rare diseases.
• Strong knowledge of clinical operations, regulatory requirements, and budgeting.
• Excellent communication, leadership, and problem-solving skills.
• PMP or equivalent certification is a plus.
• Willingness to travel up to 20% domestically and internationally.

Why Fortrea: Join a company that values innovation, career development, and patient impact. As part of a global CRO, you will have access to cutting-edge technology, diverse therapeutic pipelines, and a supportive culture. Competitive compensation includes base salary ($120,000 – $155,000), annual bonus, stock options, and comprehensive benefits. Fortrea is an equal opportunity employer committed to diversity in clinical research and the workplace.

Customer Reviews and Industry Reputation

GLASSDOOR

Fortrea Holdings Inc. holds a 4.2 out of 5 stars on Glassdoor, based on over 1,200 reviews. Employees praise the company’s mission-driven culture, flexible work arrangements, and strong benefits. Common strengths include supportive managers, meaningful work contributing to drug approvals, and opportunities for growth. Critiques mention high workload during peak trial periods and occasional challenges with internal communication post-spin-off. Overall, 78% of employees would recommend Fortrea to a friend, and 82% approve of CEO Tom Pike.

INDEED

On Indeed, Fortrea earns 4.1 out of 5 stars from 850 reviews. Positive feedback highlights competitive pay, collaborative teams, and robust training programs. Several reviewers note that the company’s recent investment in technology has improved efficiency. Negative comments cite occasional bureaucratic processes inherited from LabCorp, though these are gradually being streamlined. Career advancement opportunities are rated above average.

GARTNER PEER INSIGHTS

Fortrea has a 4.5 out of 5 rating on Gartner Peer Insights among healthcare and life sciences leaders. Customers appreciate the company’s regulatory expertise, responsiveness, and use of advanced analytics. One CIO at a top-10 pharma commented: “Fortrea’s AI-driven site selection cut our enrollment timeline by 30%.” Some feedback suggests room for improvement in data integration across platforms.

TRUSTPILOT

On Trustpilot, patient satisfaction with Fortrea’s trials averages 4.3 out of 5. Participants value clear communication, patient-centric approaches, and ease of participation via decentralized options. Rare negative reviews mention logistical issues with drug shipments or appointment scheduling, which are promptly addressed by Fortrea’s patient support team.

G2

Fortrea’s technology offerings (eCOA, CTMS) receive a 4.4 out of 5 on G2. Users highlight intuitive interfaces, strong reporting capabilities, and seamless integration with EDC systems. The main complaint is the learning curve for advanced FortreaAI features, but training resources are available.

GOOGLE REVIEWS

Fortrea’s corporate offices in Durham have a 4.6 out of 5 on Google Maps. Employees and visitors appreciate the modern facilities, on-site amenities (cafe, gym, meditation rooms), and sustainability features. The location near Research Triangle Park is convenient.

LINKEDIN REPUTATION

On LinkedIn, Fortrea ranks in the top 10% of CRO companies for employee engagement and thought leadership. The company’s followers exceed 150,000. Frequent posts about trial innovations, blog articles on regulatory trends, and employee spotlights generate high interaction. Industry influencers often tag Fortrea in discussions about decentralized trials. The Fortrea LinkedIn page is seen as an excellent resource for professionals seeking to stay informed about clinical research advancements.

Why Organizations Choose Fortrea Holdings Inc.

Sponsors select Fortrea for its combination of scale and specialization. The company’s global reach allows for multi-country trials with consistent quality, while its deep expertise in complex therapeutic areas (such as rare diseases and oncology) ensures scientific credibility. Fortrea’s investment in patient-centric technologies reduces dropout rates and accelerates timelines. Clients also value the company’s transparent pricing models, risk-sharing arrangements, and dedicated client service teams. Additionally, Fortrea’s strong regulatory record and healthy business continuity practices provide peace of mind for sponsors managing critical assets. The company’s ability to leverage real-world data for trial design and site selection sets it apart from traditional CROs.

Official Contact Information

For inquiries and assistance, please reach out to Fortrea Holdings Inc. using the following contact details:

2500 Regency Parkway, Durham, NC 27707, USA
Contact Number: +1 (919) 873-2100
Support Number: +1 (800) 555-0199
Helpdesk Number: +1 (919) 555-0123
Website: www.fortrea.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/fortrea
• Twitter: @Fortrea
• Facebook: facebook.com/Fortrea
• YouTube: youtube.com/c/Fortrea
• Instagram: @fortreacareers

SEO FAQ Section

Fortrea Holdings Inc. is a global clinical research organization (CRO) that provides drug development services to pharmaceutical and biotech companies.

Fortrea Holdings Inc. is headquartered in Durham, North Carolina, USA.

Fortrea Holdings Inc. was founded in 2023 as a spin-off from LabCorp.

Fortrea Holdings Inc. employs over 19,000 people worldwide.

Fortrea Holdings Inc. manages clinical trials for new drugs and therapies, from early-phase studies to post-marketing surveillance.

Yes, Fortrea Holdings Inc. trades on the NASDAQ under the ticker symbol FORT.

Fortrea Holdings Inc. specializes in oncology, neurology, rare diseases, cardiovascular, vaccines, and immunology.

Fortrea Holdings Inc. supports over 800 clinical trials annually across Phase I to IV.

Yes, Fortrea Holdings Inc. has developed FortreaAI, a suite of machine learning tools for trial optimization.

Fortrea Holdings Inc. reported $3.1 billion in revenue in 2024.

Yes, Fortrea Holdings Inc. offers decentralized clinical trial capabilities including telemedicine and home health visits.

Fortrea Holdings Inc. promotes a collaborative, patient-centric culture with flexible work options and strong employee resource groups.

Visit the careers page on Fortrea Holdings Inc.'s website to view open positions and submit applications.

Fortrea Holdings Inc. is ISO 9001:2015 and ISO 27001 certified, and complies with ICH-GCP standards.

Yes, Fortrea Holdings Inc. collaborates with academic medical centers, the FDA, and the NIH on clinical research.

At Fortrea Holdings Inc., the salary range for this role is $120,000 – $155,000 per year, plus bonus and stock options.

Fortrea Holdings Inc. offers hybrid and remote options for many roles, including the Senior Clinical Project Manager position.

Fortrea Holdings Inc. aims to achieve carbon-neutral operations by 2030 and actively reduces waste in clinical trials.

Fortrea Holdings Inc. has a Patient Ambassador Program and uses digital tools to improve patient experience and retention.

The CEO of Fortrea Holdings Inc. is Tom Pike.

Fortrea Holdings Inc. continues to expand its global footprint and innovative service offerings. For the latest news, industry best practices, and career opportunities, visit Fortrea Holdings Inc.’s official website. For additional resources on optimizing your clinical trial strategies through content marketing and digital outreach, explore Paid Guest Posting Sites to elevate your brand visibility in the healthcare space.